Phil Vanek

Phil Vanek is the chief commercialization officer of the International Society for Cell and Gene Therapy (ISCT), a global professional society for the cell- and gene-therapy field. He has spent his career in the science and commercialization of advanced therapies, spanning product development, innovation leadership, and, in recent years, private-equity investing.

Vanek earned a PhD in biochemistry and molecular biology from Georgetown University Medical Center, with research in molecular oncology, and completed postdoctoral training at the National Cancer Institute. He began on the laboratory bench before moving into business and innovation roles. Over his career he served as general manager of cell and gene therapy strategy at GE Healthcare Life Sciences and as head of innovation for Lonza’s pharmaceutical division, and held senior business and market-development roles at Becton Dickinson, Invitrogen, and Life Technologies, as well as at two Washington, D.C.-area biotechnology startups. He later served as chief technology officer of Gamma Biosciences, a life-sciences investment platform, and is the founder and chief executive of Redline Bioadvisors, a strategic advisory firm serving investors and life-sciences organizations.

Vanek also teaches and advises across the field: he has been an instructor in Johns Hopkins University’s biotechnology program, mentors with the Creative Destruction Lab, serves as an entrepreneur in residence at Georgetown University Medical Center, sits on the boards of CCRM Enterprises and the Foundation for Cell and Gene Medicine, and serves as an officer of the executive committee of the Alliance for Regenerative Medicine.

Vanek appeared on Open Door Salon alongside Andy Holt, chief commercial officer of the AAV manufacturer Viralgen, for a conversation on why cell and gene therapies remain costly and what affordability would require. Drawing on his experience as both an operator and an investor, Vanek argued that the field’s challenges are as much about alignment and education as about science: clinicians, patients, payers, investors, and regulators often lack a shared language for technologies that are advancing faster than the systems meant to deliver them.

His advice to founders and investors was disciplined and direct: avoid hype, use capital efficiently, lean on the community of practitioners who have done the work, and stay focused on moving a single therapy forward rather than chasing the next attractive idea.